The former study refers to the combination of cabozantinib and atezolizumab versus sorafenib in patients with advanced HCC who receive their first-line of treatment and the latter regards the combination of tremelimumab, with an anti-PDL-1 immune agent, named durvalumab, which revealed tolerable toxicity and encouraging activity in patients with advanced HCC [36,40,41]. The gene discussed is CD274; the disease is hepatocellular carcinoma.